Business
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
SAN DIEGO, June 25, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progres
About this update from Contineum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1875,"height":663,"url":"https://media.zenfs.com/en/business-wire.com/3b9614a3a7cf552da6e502db2bbdc710"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gmnFwxzX56_uMWHbrjaIXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3b9614a3a7cf552da6e502db2bbdc710","width":960,"height":339},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uzc1gaBlRf4.ZevvmLDmCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3b9614a3a7cf552da6e502db2bbdc710","width":1200,"height":424}},"lazy":false},{"type":"text","content":"SAN DIEGO, June 25, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing.","length":692,"tagName":"p"},{"type":"text","content":""In early June, consistent with our protocol, we enrolled two additional PrMS patients to assess PET imaging of the brain," said Timothy Watkins, M.D., M.Sc., Chief Medical Officer and Head of Development, Contineum Therapeutics. "While adding these additional patients to the trial has led to a modest delay in reporting our topline data, we believe the enhanced clinical understanding of PIPE-791 in patients is important to the program. This trial builds on our compelling preclinical data and improves our understanding of receptor occupancy in healthy volunteers and patients, helping guide our dose selection in the next stages of clinical development. We now anticipate reporting topline data from these fully enrolled cohorts in the third quarter of 2025."","length":784,"tagName":"p"},{"type":"text","content":"The Phase 1b, open label, single-cente...